Date: 2011-04-05
Type of information: Presentation of results at a congress
phase: 1-2
Announcement: results
Company: Transgene (France) Jennerex (USA)
Product: JX-594/TG6006 (Pexa-Vec)
Action
mechanism:
Disease: hepatocellular carcinoma
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest news: Transgene and Jennerex have announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) over the weekend at the Internationales Congress Centrum in Berlin, Germany. This presentation highlighted data from 35 patients with either primary liver cancer, known as hepatocellular carcinoma, or cancer metastases to the liver (including colorectal cancer, melanoma and renal cancer). All patients were given intratumoral injections (up to eight treatments) over the course of JX-594 therapy. Twenty-three patients (66%) exhibited significant tumor necrosis and responses by modified Choi criteria (decreased tumor density). Choi responses have also been documented in non-injected tumors, consistent with prior data on JX-594. Seven patients (20% of evaluable) also exhibited objective response by Response Evaluation Criteria in Solid Tumor (RECIST) criteria, including two complete responses upon long-term follow-up. Twenty patients (57%) had stable disease as defined by RECIST criteria.